These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021. Wise MG; Karlowsky JA; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF J Formos Med Assoc; 2024 Mar; 123(3):400-407. PubMed ID: 37735013 [TBL] [Abstract][Full Text] [Related]
6. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021. Karlowsky JA; Lob SH; Hawser SP; Kothari N; Siddiqui F; Alekseeva I; DeRyke CA; Young K; Motyl MR; Sahm DF Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1343-1348. PubMed ID: 38775873 [TBL] [Abstract][Full Text] [Related]
7. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019. Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR; Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144 [TBL] [Abstract][Full Text] [Related]
8. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Karlowsky JA; Lob SH; Hawser SP; Kothari N; Siddiqui F; Alekseeva I; DeRyke CA; Young K; Motyl MR; Sahm DF JAC Antimicrob Resist; 2023 Aug; 5(4):dlad098. PubMed ID: 37577157 [TBL] [Abstract][Full Text] [Related]
9. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019. Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945 [No Abstract] [Full Text] [Related]
10. Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents-SMART 2018-21. Karlowsky JA; Wise MG; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF JAC Antimicrob Resist; 2024 Feb; 6(1):dlad149. PubMed ID: 38161963 [TBL] [Abstract][Full Text] [Related]
11. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021). Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. Sader HS; Castanheira M; Duncan LR; Mendes RE Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144 [TBL] [Abstract][Full Text] [Related]